Onderneming Monte Rosa Therapeutics, Inc.
Aandelen
GLUE
US61225M1027
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
5,32 USD | -5,17% | -3,97% | -5,84% |
29/04 | MONTE ROSA THERAPEUTICS, INC. : UBS geeft koopadvies | ZM |
14/03 | Monte Rosa Therapeutics nettoverlies over Q4 kleiner; aandelen dalen | MT |
Vakgebied
Aantal werknemers: 133
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Markus Warmuth
CEO | Chief Executive Officer | 53 | 01-01-20 |
Chief Operating Officer | - | 01-03-21 | |
Filip Janku
CTO | Chief Tech/Sci/R&D Officer | 50 | 01-06-21 |
Sharon Townson
CTO | Chief Tech/Sci/R&D Officer | 49 | 01-07-20 |
Owen Wallace
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-02-21 |
John Castle
CTO | Chief Tech/Sci/R&D Officer | 54 | 01-05-20 |
Philip Nickson
LAW | General Counsel | 45 | 01-03-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Andrew Schiff
BRD | Director/Board Member | 58 | 01-09-20 |
Christine Siu
BRD | Director/Board Member | 47 | 01-12-20 |
Chandra Paul Leo
BRD | Director/Board Member | 55 | 01-09-20 |
Ali Behbahani
BRD | Director/Board Member | 47 | 01-04-20 |
Anthony Manning
BRD | Director/Board Member | 62 | 25-07-23 |
Markus Warmuth
CEO | Chief Executive Officer | 53 | 01-01-20 |
Jan Skvarka
BRD | Director/Board Member | 57 | 23-03-23 |
Director/Board Member | 55 | 01-06-20 | |
Alexander Mayweg
CHM | Chairman | 49 | 01-04-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 50 340 020 | 49 892 025 ( 99,11 %) | 14 696 ( 0,0292 %) | 99,11 % |
Bedrijfsgegevens
Sector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-5,84% | 268 mln. | |
+0,17% | 42,19 mld. | |
+10,92% | 42,24 mld. | |
+44,30% | 40,15 mld. | |
-6,20% | 28,31 mld. | |
+5,23% | 24,63 mld. | |
-24,79% | 18,2 mld. | |
+26,69% | 12,01 mld. | |
-3,13% | 11,76 mld. | |
+6,57% | 10,4 mld. |
- Beurs
- Aandelen
- Koers GLUE
- Onderneming Monte Rosa Therapeutics, Inc.